Literature DB >> 3792433

Digoxin-diltiazem interaction: a pharmacokinetic evaluation.

W N Jones, K B Kern, J P Rindone, M Mayersohn, M Bliss, S Goldman.   

Abstract

The pharmacokinetics of digoxin were studied before and after a 2 week course of diltiazem, 30 mg four times daily, in 7 healthy volunteers. Each subject received an IV dose of digoxin before starting diltiazem and again on day 15 of the study. Diltiazem was continued until all sera and urine were collected. During the control and diltiazem phases, respectively, the terminal elimination rate constants were 0.0231 +/- 0.007 h-1 and 0.0254 +/- 0.007 h-1, the volumes of distribution were 10.5 +/- 3.95 l/kg and 10.2 +/- 3.26 l/kg, and the total body clearances were 3.72 +/- 0.78 ml X min-1 X kg-1 and 4.09 +/- 0.94 ml X min-1 X kg-1. None of these pharmacokinetic parameters of digoxin were significantly different before or during diltiazem administration. Overall, there does not appear to be an interaction between digoxin and diltiazem.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3792433     DOI: 10.1007/bf00981136

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Effects of nifedipine and diltiazem on plasma levels and renal excretion of beta-acetyldigoxin.

Authors:  J Kuhlmann
Journal:  Clin Pharmacol Ther       Date:  1985-02       Impact factor: 6.875

2.  Digoxin plasma concentrations and nifedipine.

Authors:  G G Belz; P E Aust; R Munkes
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

3.  Digoxin-diltiazem interaction.

Authors:  Y Oyama; S Fujii; K Kanda; E Akino; H Kawasaki; M Nagata; K Goto
Journal:  Am J Cardiol       Date:  1984-05-15       Impact factor: 2.778

4.  Interaction between digoxin and calcium antagonists and antiarrhythmic drugs.

Authors:  G G Belz; W Doering; R Munkes; J Matthews
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

5.  Lack of effects of diltiazem on digoxin pharmacokinetics.

Authors:  T R Beltrami; J J May; J S Bertino
Journal:  J Clin Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.126

6.  Digoxin-verapamil interaction.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

7.  Effect of nifedipine on serum digoxin concentration and renal digoxin clearance.

Authors:  J B Schwartz; P J Migliore
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

8.  The diltiazem-digoxin interaction.

Authors:  H Rameis; D Magometschnigg; U Ganzinger
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

9.  The influence of verapamil on serum digoxin concentration.

Authors:  H O Klein; R Lang; E Weiss; E Di Segni; C Libhaber; J Guerrero; E Kaplinsky
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

10.  Effect of nifedipine on digoxin kinetics in healthy subjects.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; K Kjaer; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

View more
  5 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 3.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.